Immune checkpoint inhibitor (ICPI)-mediated diarrhea and colitis is the leading cause of discontinuation of ICPI therapy in patients with malignancy. Existing literature on predictors of adverse outcomes is limited. We evaluated the association between risk factors, concomitant Clostridioides difficile infection (CDI), and abdominal CT scan findings of colitis on outcomes in patients with ICPI-related diarrhea and colitis.